MrC's Smallcap Sweeps for July 2021
Posted: July 1st, 2021, 7:43 am
Smallcap Sweep. 01-Jul-21
Biome bio-degrades expectations
Headlam (HEAD) YTD rev in line with 2019 having been slightly below for the four months to 30 April. [SP=438 Cap=373m]
Biome (BIOM) warns FY21 & 22 rev materially below market expectations. The customer for compostable coffee-pod filtration material has a problem in its factory which will cause months delay entering production. Will have a significant impact on growth in the nearer term. Also shipping delays "are now proving a significant constraint on the division's ability to quickly undertake the multiple development iterations that are required to support growth with new customers." RF div trading OK. [SP=473.1 Cap=18m]
ATLAS Mara (ATMA) trading halted due to failure to publish FY accounts. Blames ongoing strategic review and engagement with the creditors. [SP=0.43 Cap=64m]
Xeros Technology (XSG) co-operation agreement with Hanning Elektro-Werke to test and market XFiltra to domestic washing machine manufacturers. Hanning is a leading manufacturer of component parts for major industries. [SP=231.2 Cap=55m]
Petards (PEG) £0.5m contract to supply ProVida systems to a new overseas customer. Delivery H2 2021. [SP=12.11 Cap=7m]
Sareum (SAR) top-line results from SDC-1801 covid treatment project confirm initial encouraging results reported. [SP=5.75 Cap=192m]
Genedrive (GDR) good progress with rapid covid test. "In contrast to many competitor products, the test targets two genes of the SARS-CoV-2 genome, and is shown to be inclusive of all current Variants of Concern." [SP=56.75 Cap=36m]
Revolution Bars (RBG) guides FY(July) ahead of mgmt expectations with EBITDA loss (pre IFRS16 adjustments) c.£12.5m. Rev since indoor re-opening down 14% from 2019. Co "confident that significant further pent up demand exists and therefore further strong trading is anticipated" [SP=21.25 Cap=49m]
Zoetic (ZOE) $0.72m order from US distributor. Chill website UK launch. [SP=52 Cap=110m]
AO World (AO.) FY(Mar) rev up 62% in line. EPS 3.73p (0.21p). Outlook - "We have started the new financial year well and remain prudently optimistic that we will be able to deliver double digit growth as we lap the strong Covid performance comparatives." [SP=253 Cap=1213m]
Cambridge Cognition (COG) Spin-out of 63% of Monument Therapeutics which gets £2.6m in funding from a consortium of investors. Monument is a drug development company applying digital phenotyping to central nervous system disorders. [SP=165 Cap=51m]
Gresham House Energy Storage Fund (GRID) £100m placing at 112p, a 7% discount, to finance projects. [SP=120.91 Cap=421m]
In line: ALT
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian
Biome bio-degrades expectations
Headlam (HEAD) YTD rev in line with 2019 having been slightly below for the four months to 30 April. [SP=438 Cap=373m]
Biome (BIOM) warns FY21 & 22 rev materially below market expectations. The customer for compostable coffee-pod filtration material has a problem in its factory which will cause months delay entering production. Will have a significant impact on growth in the nearer term. Also shipping delays "are now proving a significant constraint on the division's ability to quickly undertake the multiple development iterations that are required to support growth with new customers." RF div trading OK. [SP=473.1 Cap=18m]
ATLAS Mara (ATMA) trading halted due to failure to publish FY accounts. Blames ongoing strategic review and engagement with the creditors. [SP=0.43 Cap=64m]
Xeros Technology (XSG) co-operation agreement with Hanning Elektro-Werke to test and market XFiltra to domestic washing machine manufacturers. Hanning is a leading manufacturer of component parts for major industries. [SP=231.2 Cap=55m]
Petards (PEG) £0.5m contract to supply ProVida systems to a new overseas customer. Delivery H2 2021. [SP=12.11 Cap=7m]
Sareum (SAR) top-line results from SDC-1801 covid treatment project confirm initial encouraging results reported. [SP=5.75 Cap=192m]
Genedrive (GDR) good progress with rapid covid test. "In contrast to many competitor products, the test targets two genes of the SARS-CoV-2 genome, and is shown to be inclusive of all current Variants of Concern." [SP=56.75 Cap=36m]
Revolution Bars (RBG) guides FY(July) ahead of mgmt expectations with EBITDA loss (pre IFRS16 adjustments) c.£12.5m. Rev since indoor re-opening down 14% from 2019. Co "confident that significant further pent up demand exists and therefore further strong trading is anticipated" [SP=21.25 Cap=49m]
Zoetic (ZOE) $0.72m order from US distributor. Chill website UK launch. [SP=52 Cap=110m]
AO World (AO.) FY(Mar) rev up 62% in line. EPS 3.73p (0.21p). Outlook - "We have started the new financial year well and remain prudently optimistic that we will be able to deliver double digit growth as we lap the strong Covid performance comparatives." [SP=253 Cap=1213m]
Cambridge Cognition (COG) Spin-out of 63% of Monument Therapeutics which gets £2.6m in funding from a consortium of investors. Monument is a drug development company applying digital phenotyping to central nervous system disorders. [SP=165 Cap=51m]
Gresham House Energy Storage Fund (GRID) £100m placing at 112p, a 7% discount, to finance projects. [SP=120.91 Cap=421m]
In line: ALT
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.
RNSs
http://www.investegate.co.uk/index.aspx?limit=-1
@MrContrarian